Guerbet : Une trajectoire davantage sous contrôle – Prévisions et OC ajustés en légère hausse
>Une meilleure visibilité : des leviers produits et un éco-système plus stable - De la réunion tenue ce matin, nous retiendrons les éléments suivants :1/ Elucirem : après la phase « d’échantillonnage », aux USA (approval en Sept. 2022), Guerbet entre dans la phase de « re-order des clients » : la moitié des clients d’Elucirem sont de nouveaux clients. Le produit permet d’ouvrir de nouveaux comptes et permet de gagner des parts de marché. Lancé en Allemagne et au ...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.